奥力欣品牌怎么样 申请店铺

更新时间:2024-10-29
奥力欣是哪个国家的品牌?「奥力欣」是 安徽奥力欣生物科技有限公司 旗下著名品牌。该品牌发源于安徽省安庆市,由创始人丁国平在2002-08-09期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
奥力欣怎么样

安徽奥力欣生物科技有限公司成立于2002年,是集生物技术开发、饲料添加剂、兽药研发等加工生产、销售为一体企业。公司法定代表人丁国平,注册资本6000万元,专注于生物技术、兽用药物、动保用品、饲料及添加剂的研发、生产、技术服务和市场营销,在中兽制药尤其是在新剂型、新技术领域拥有雄厚的技术力量和新产品开发能力。

公司拥有兽医药、制药工程等专业人才60余人,其中博士、硕士10人;拥有自主知识产权的新产品8个,兽药新品种60余种;现厂房设施总建筑面积56000㎡,制药生产、检测设备400余台套。质检中心设有理化室、仪器分析室、中药室,配备有液相色谱仪、分光光度计等精密仪器,设施、设备优良、齐全。公司在充分发挥自身技术优势同时,利用外脑资源,与国内多个研究机构进行合作,研发的新药品种如“禽呼吸道病防治合剂”、“芪根可溶性粉”等多个国家Ⅲ类新兽药,临效显著。

目前奥力欣企业技术中心、兽用药物生物工程中心已经逐步实施运营,企业后续将以双中心为依托,以“奥力欣中药科技产业化项目”为契机,着眼于中兽药的研发、生产和营销,夯实基础,以人为本,专注于公司企业文化的建设和管理,同时专注于奥力欣品牌的打造与创新,以逐步建成动物疾病研究硕士工作站、国家技术研究中心等。伴随着全球经济一体化的时代趋势和当前公司制定的战略规划,奥力欣未来5年的展望:“打造中兽药奥力欣®品牌, 成为国内兽用药物产品市场带领者”,在新形势下实现步发展。


Anhui aolixin Biotechnology Co., Ltd. was founded in 2002. It is an enterprise integrating the processing, production and sales of biotechnology development, feed additives, veterinary medicine research and development. Ding Guoping, the legal representative of the company, with a registered capital of 60 million yuan, focuses on the R & D, production, technical service and marketing of biotechnology, veterinary drugs, animal protection products, feed and additives, and has strong technical force and new product development capacity in China veterinary pharmaceutical, especially in the field of new dosage forms and new technologies. The company has more than 60 professional talents in veterinary medicine, pharmaceutical engineering, etc., including 10 doctors and masters; 8 new products with independent intellectual property rights, more than 60 new varieties of veterinary medicine; the total building area of plant facilities is 56000m2, and more than 400 sets of pharmaceutical production and testing equipment. The quality inspection center is equipped with physical and chemical room, instrument analysis room, Chinese medicine room, liquid chromatograph, spectrophotometer and other precision instruments, with excellent facilities and complete equipment. At the same time, the company makes full use of its own technical advantages, uses external brain resources, and cooperates with a number of domestic research institutions to develop new drug varieties such as "bird respiratory disease prevention and treatment mixture", "Qigen soluble powder" and other national class III new veterinary drugs with significant clinical effects. At present, aolixin enterprise technology center and veterinary medicine bioengineering center have been gradually put into operation. In the future, the enterprise will rely on the two centers and take the opportunity of "aolixin TCM technology industrialization project", focus on the R & D, production and marketing of Chinese veterinary medicine, consolidate the foundation, people-oriented, focus on the construction and management of corporate culture, and focus on the brand of aolixin Build and innovate to gradually build master's workstation of animal disease research, national technology research center, etc. With the trend of global economic integration and the current strategic plan formulated by the company, alixin's outlook for the next five years: "to build the brand of Chinese veterinary drug alixin, and become the market leader of domestic veterinary drug products", and realize further development in the new situation.

本文链接: https://brand.waitui.com/d905db3bd.html 联系电话:15240063322

千城特选小程序码

7×24h 快讯

东方雨虹:拟5亿元-10亿元回购股份用于注销

36氪获悉,东方雨虹公告,拟5亿元-10亿元回购股份,用于注销并减少公司注册资本。回购价格不超过19.30元/股。

33分钟前

美股大型科技股盘前普涨,谷歌涨超2%

36氪获悉,美股大型科技股盘前普涨,截至发稿,谷歌涨超2%,英伟达、亚马逊、Meta涨超1%,微软涨0.91%,特斯拉涨0.53%,苹果涨0.51%。

33分钟前

热门中概股美股盘前普涨,B站涨超4%

36氪获悉,热门中概股美股盘前普涨,截至发稿,B站涨超4%,小鹏汽车涨超3%,爱奇艺、蔚来涨超2%,阿里巴巴、京东、拼多多、百度涨超1%。

33分钟前

2连板申科股份:近期公司经营情况正常,内外部经营环境未发生重大变化

36氪获悉,申科股份公告,公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较大影响的未公开重大信息。近期公司经营情况正常,内外部经营环境未发生重大变化。公司10月24日公告,公司控股股东、实际控制人何全波拟将其持有公司全部股份42187466股股权(无限售流通股,占公司总股本的28.12%)股份以公开征集意向受让方方式进行协议转让。

33分钟前

2024年10月票房破35亿

36氪获悉,据灯塔专业版,截止10月28日20时48分,2024年10月总票房(含预售)突破35亿,《志愿军:存亡之战》《浴火之路》《749局》暂列票房前三位。​​​

33分钟前

本页详细列出关于奥力欣的品牌信息,含品牌所属公司介绍,奥力欣所处行业的品牌地位及优势。
咨询